EGFR inhibitors: clinical results

Suppl Tumori. 2002 Nov-Dec;1(6):S5-6. doi: 10.1177/03008916020016s102.
No abstract available

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Breast Neoplasms / drug therapy
  • Carcinoma, Non-Small-Cell Lung / drug therapy
  • Cell Differentiation
  • Cell Division
  • Cell Survival
  • Clinical Trials as Topic
  • Epidermal Growth Factor / antagonists & inhibitors
  • ErbB Receptors / antagonists & inhibitors*
  • Female
  • Gefitinib
  • Gene Expression Regulation, Neoplastic*
  • Head and Neck Neoplasms / drug therapy
  • Humans
  • Ligands
  • Lung Neoplasms / drug therapy
  • Ovarian Neoplasms
  • Protein-Tyrosine Kinases / antagonists & inhibitors
  • Quinazolines / adverse effects
  • Quinazolines / pharmacology*
  • Survival

Substances

  • Antineoplastic Agents
  • Ligands
  • Quinazolines
  • Epidermal Growth Factor
  • ErbB Receptors
  • Protein-Tyrosine Kinases
  • Gefitinib